Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT06479057 En recrutement IDF

Titre

Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)

Type

Observational [Patient Registry]

Pathologie

Tumeurs

Phase

Promoteur

Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)

Date de début

janvier 2024

Date de fin

juillet 2027

Dernière mise à jour

02 février 2026

Résumé

PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care. This is an observational cohort study in the context of a quality-of-care initiative. It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.

Détail

Voir le détail The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway. Secondary study endpoints include: 1. To evaluate the Reach of each pathway through the number of patients who participated in supportive care needs' assessment and in each supportive care intervention (administrative review of attendance log) 2. To evaluate the diversity of patients included in each pathways through evaluation of sociodemographic and economic profile (Socioeconomic and demographic self-reported questionnaire) 3. To evaluate the impact of each pathway and each supportive care intervention on patient's overall health status (EQ-E5-EL) 4. To evaluate the impact of each pathway and each supportive care intervention on patient's quality of life (EORTC QLQ C30) 5. To evaluate the impact of each pathway and each supportive care intervention on symptom burden (MDASI) 6. To evaluate the impact of each pathway and each supportive care intervention on anxiety (HADS) 7. To evaluate the impact of each pathway and each supportive care intervention on Insomnia levels (ISI) 8. To evaluate the impact of each pathway and each supportive care intervention on sexual health (EORTC SHQ-C22) 9. To evaluate the Physician's Adoption of each pathway through the proportion of physicians referring patients to the pathways (referral log) 10. To evaluate patient's adoption through the proportion of patients adhering to supportive care interventions as intended (attendance log) 11. To evaluate patient experience and satisfaction with the pathways (PACIC and adhoc satisfaction questionnaires. 12. To evaluate implementation in through a qualitative analyses of experience, implementation barriers and facilitators (focus groups with patients and providers) 13. To plan for Maintenance of the pathway through a cost effectiveness analysis. 14. To evaluate the impact of each pathway and each supportive care intervention on Intestinal Symptoms (LARS score). if indicated for the specific population 15. To evaluate the impact of each pathway and each supportive care intervention on Anal Incontinence (Wexner score). if indicated for the specific population 16. To evaluate the impact of each pathway and each supportive care intervention on Urinary Symptoms (USP score). if indicated for the specific population 17. To evaluate the impact of each pathway and each supportive care intervention on Hematologic Cancer (FACT-BMT) 18. To evaluate the impact of each pathway and each supportive care intervention on Montgomery Borgatta Caregiver Burden Scale. if indicated for the specific population. 19. To evaluate the healthcare professionals participating in the pathway to screen vulnerability and prevent treatment related burden (F-SUS) This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies. Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention). Fermer le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY	Maria Alice FRANZOI	En recrutement IDF	28/06/2024 11:44:31	Contacter
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY	Ines VAZ LUIS			Contact (sur clinicalTrials)

Critères

Genre

Tous

Nombre d'inclusion

Critère d'inclusion

- Histological confirmation of cancer (any cancer type, any stage)

- Age ≥ 18 years old

- Received an integrated supportive care need assessment.

- Sign the consent form for the PROACT study.

Exclusion Criteria:

Critère de non inclusion

- Absence or inability of written consent from the patient.

- Does not understand or speak French.

NCT06479057 - Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut